Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jun 21;131(25):2742-2743.
doi: 10.1182/blood-2018-05-843151.

Warfarin, a juggler's demise

Affiliations
Comment

Warfarin, a juggler's demise

Laurent O Mosnier. Blood. .

Abstract

Warfarin, an anticoagulant therapy used by millions worldwide, inhibits vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby dampening the carboxylation and the procoagulant potential of vitamin K–dependent coagulation factors. However, the detailed molecular mechanism by which warfarin inhibits VKORC1 remains the subject of debate., In this issue of Blood, Rishavy et al puts this issue to rest by demonstrating that warfarin inhibits VKORC1 via a mechanism termed “the uncoupling of VKORC1.” The uncoupling of VKORC1 is significant because it highlights a potential cooperation of VKORC1 with a second warfarin-resistant vitamin K quinone reductase, thereby explaining how considerable carboxylation can proceed despite the presence of warfarin, and this may have direct implications for warfarin dosing in patients.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
Inhibition of the vitamin K cycle by warfarin. KH2 is converted to KO during the carboxylation of Glu to Gla residues by γ-glutamyl carboxylase. Under normal physiologic conditions in the liver, VKORC1 efficiently recycles KO back to KH2 in a 2-step reaction, generating K as an intermediate product (left side). The uncoupling of the 2 VKORC1-mediated reactions (KO→K and K→KH2) in the presence of warfarin, as described by Rishavy et al, causes a loss in efficiency of VKORC1 for the full recycling of KO to KH2 and a loss in carboxylation. However, because warfarin uncouples the reaction rather than directly inhibits the reaction, VKORC1 can still generate considerable amounts of the K intermediary. The completion of the final step (K→KH2) then becomes dependent on the extent to which the second warfarin-resistant vitamin K quinone reductase (2nd VKR) is present and active. Thus, although VKORC1 is responsible for the full recycling of KO to KH2 in the absence of warfarin, the recycling pathway changes in the presence of warfarin and requires cooperation of VKORC1 and the 2nd VKR. The degree of carboxylation in the presence of warfarin is therefore dependent on the expression and activity of 2nd VKR (indicated by the dotted arrows), the identity of which remains unknown to date.

Comment on

Similar articles

Cited by

References

    1. Rishavy MA, Hallgren KW, Wilson LA, Usubalieva A, Runge KW, Berkner KL. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation. J Biol Chem. 2013;288(44):31556-31566. - PMC - PubMed
    1. Tie JK, Jin DY, Straight DL, Stafford DW. Functional study of the vitamin K cycle in mammalian cells. Blood. 2011;117(10):2967-2974. - PMC - PubMed
    1. Rishavy MA, Hallgren KW, Wilson L, Singh S, Runge KW, Berkner KL. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood. 2018;131(25):2826-2835. - PMC - PubMed
    1. Oldenburg J, Marinova M, Müller-Reible C, Watzka M. The vitamin K cycle. Vitam Horm. 2008;78:35-62. - PubMed
    1. Rost S, Fregin A, Ivaskevicius V, et al. . Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537-541. - PubMed